A170900 Stock Overview
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Dong-A ST Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩57,800.00 |
| 52 Week High | ₩88,000.00 |
| 52 Week Low | ₩54,200.00 |
| Beta | 0.64 |
| 1 Month Change | -4.62% |
| 3 Month Change | -19.16% |
| 1 Year Change | -16.35% |
| 3 Year Change | -16.01% |
| 5 Year Change | -47.02% |
| Change since IPO | -59.50% |
Recent News & Updates
Dong-A ST Co., Ltd. (KRX:170900) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Dec 09
Is Dong-A ST (KRX:170900) A Risky Investment?
Oct 16Investor Optimism Abounds Dong-A ST Co., Ltd. (KRX:170900) But Growth Is Lacking
Aug 21Recent updates
Dong-A ST Co., Ltd. (KRX:170900) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Dec 09Is Dong-A ST (KRX:170900) A Risky Investment?
Oct 16Investor Optimism Abounds Dong-A ST Co., Ltd. (KRX:170900) But Growth Is Lacking
Aug 21Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 25Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Mar 07Does Dong-A ST (KRX:170900) Have A Healthy Balance Sheet?
Apr 09Dong-A ST's (KRX:170900) Problems Go Beyond Weak Profit
Mar 23A Look At The Fair Value Of Dong-A ST Co., Ltd. (KRX:170900)
Mar 12A Look At Dong-A ST's (KRX:170900) Share Price Returns
Feb 24Is Dong-A ST Co., Ltd.'s (KRX:170900) Stock's Recent Performance A Reflection Of Its Financial Health?
Feb 09
Is Dong-A ST Co., Ltd. (KRX:170900) Popular Amongst Institutions?
Jan 25Is Dong-A ST Co., Ltd. (KRX:170900) A Good Fit For Your Dividend Portfolio?
Jan 11Be Sure To Check Out Dong-A ST Co., Ltd. (KRX:170900) Before It Goes Ex-Dividend
Dec 25Dong-A ST (KRX:170900) Has A Rock Solid Balance Sheet
Dec 22Calculating The Intrinsic Value Of Dong-A ST Co., Ltd. (KRX:170900)
Dec 07A Look At Dong-A ST's (KRX:170900) Share Price Returns
Nov 19Shareholder Returns
| A170900 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.8% | 2.3% | -0.5% |
| 1Y | -16.4% | -1.0% | -11.6% |
Return vs Industry: A170900 underperformed the KR Pharmaceuticals industry which returned -1% over the past year.
Return vs Market: A170900 underperformed the KR Market which returned -11.6% over the past year.
Price Volatility
| A170900 volatility | |
|---|---|
| A170900 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A170900 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A170900's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1932 | n/a | n/a | www.donga-st.com |
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta inj.
Dong-A ST Co., Ltd. Fundamentals Summary
| A170900 fundamental statistics | |
|---|---|
| Market cap | ₩533.62b |
| Earnings (TTM) | -₩24.22b |
| Revenue (TTM) | ₩700.31b |
0.7x
P/S Ratio-21.4x
P/E RatioIs A170900 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A170900 income statement (TTM) | |
|---|---|
| Revenue | ₩700.31b |
| Cost of Revenue | ₩358.42b |
| Gross Profit | ₩341.89b |
| Other Expenses | ₩366.11b |
| Earnings | -₩24.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.70k |
| Gross Margin | 48.82% |
| Net Profit Margin | -3.46% |
| Debt/Equity Ratio | 78.8% |
How did A170900 perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield-7%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 16:24 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dong-A ST Co., Ltd. is covered by 20 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dae Woong Yoo | Bookook Securities Co. Ltd |
| Ka-hye Hong | Daishin Securities Co. Ltd. |
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |